Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Epitomics Inc.
Another week has seen another plethora of deals between Chinese domestic players and global gene sequencing firms. Rising demand for individualized treatments and the rush for cancer immuno-therapies is propelling fast growth for the US-Chinese biotech company Crownbio, says its executive chairman Guo-Liang Yu.
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
In a golden age of biotech in China, Crown is transforming from a biologics development service company to a mixed biotech through a planned IPO in Taiwan. Backed by its world-largest patient-derived xenograft models bank, the company is discovering oncology compounds.
Glaxo sold a European portfolio of non-core OTC products to Omega Pharma for $614 million. Device companies Zoll Medical and Cameron Health were acquired in two separate billion-dollar-plus deals. Biopharma funding reached $1 billion and device firms raised $539 million.
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
Laboratory Testing Services
- Anatomical Pathology